

1 Integration of Group A Streptococcus Rapid Tests with the Open Fluidic CandyCollect Device

2
3 J. Carlos Sanchez*¹, Ingrid H. Robertson*¹, Victoria A. M. Shinkawa*¹, Xiaojing Su¹, Wan-chen
4 Tu¹, Timothy R. Robinson², Megan M. Chang³, Andrea Blom⁴, Elena Alfaro⁴, Daniel B. Hatchett¹,
5 Ayokunle O. Olanrewaju^{2,3}, Ellen R. Wald⁴, Gregory P. DeMuri⁴, Erwin Berthier¹, Sanitta
6 Thongpang^{§1,5}, Ashleigh B. Theberge^{§1,6}

7 Affiliations:

8 ¹Department of Chemistry, University of Washington, Seattle, WA, USA

9 ²Department of Mechanical Engineering, University of Washington, Seattle WA, USA

10 ³Department of Bioengineering, University of Washington, Seattle WA, USA

11 ⁴Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI,
12 USA

13 ⁵Department of Biomedical Engineering, Faculty of Engineering, Mahidol University, Nakorn Pathom,
14 Thailand

15 ⁶Department of Urology, School of Medicine, University of Washington, Seattle, WA, USA

16
17
18
19 *These authors contributed equally to this work

20 §Co-corresponding authors

21
22 **Address correspondence to:** Ashleigh B. Theberge, Department of Chemistry, University
23 of Washington, Box 351700, Seattle, WA 98195-1700, [abt1@uw.edu], 206-685-2330. Sanitta
24 Thongpang, Department of Chemistry, University of Washington, Box 351700, Seattle, WA 98195-1700,
25 [sanitta@uw.edu], 206-685-2330.

26
27 **Keywords:** Diagnostics, Open Microfluidics, Point of Care, Bacterial Detection, Rapid Antigen
28 Detection Test (RADT), Computer-assisted Analysis

29 Abstract

30
31
32
33 The CandyCollect device is a lollipop-inspired open fluidic oral sampling device designed to provide a
34 comfortable user sampling experience. We demonstrate that the CandyCollect device can be coupled with
35 a rapid antigen detection test (RADT) kit designed for Group A Streptococcus (GAS). Through *in vitro*
36 experiments with pooled saliva spiked with *Streptococcus pyogenes* we tested various reagents and
37 elution volumes to optimize the RADT readout from CandyCollect device samples. The resulting
38 optimized protocol uses the kit-provided reagents and lateral flow assay (LFA) while replacing the kit's
39 pharyngeal swab with the CandyCollect device, reducing the elution solution volume, and substituting the
40 tube used for elution to accommodate the CandyCollect device. Positive test results were detected by eye
41 with bacterial concentrations as low as the manufacturer's "minimal detection limit" - 1.5×10^5 CFU/mL.
42 LFA strips were also scanned and quantified with image analysis software to determine the signal-to-
43 baseline ratio (SBR) and categorize positive test results without human bias. We tested our optimized
44 protocol for integrating CandyCollect and RADT using CandyCollect clinical samples from pediatric

45 patients (n=6) who were previously diagnosed with GAS pharyngitis via pharyngeal swabs tested with
46 RADT as part of their clinical care. The LFA results of these CandyCollect devices and interspersed
47 negative controls were determined by independent observers, with positive results obtained in four of the
48 six participants on at least one LFA replicate. Taken together, our results show that CandyCollect devices
49 from children with GAS pharyngitis can be tested using LFA rapid tests.

50

51 **Introduction**

52

53 *Streptococcus pyogenes* is responsible for over 600 million cases of bacterial pharyngitis globally each
54 year.¹ Demographically, this affects 15% of school-aged children and 4-10% of adults; in developing
55 nations, the burden is much greater with rates 5-10 times higher.¹ Streptococcal pharyngitis most
56 commonly presents as a fever and sore throat an inflamed pharynx and tonsils (often with patchy white
57 exudates). Most symptoms of strep throat resolve after 3 to 4 days, however treatment in the form of
58 antibiotics is recommended to shorten the course of the infection, lessen spread, and prevent more serious
59 outcomes.¹ Untreated incidents of GAS infections may trigger several disorders including acute rheumatic
60 fever, acute poststreptococcal glomerulonephritis, and pediatric autoimmune neuropsychiatric disorders
61 associated with streptococcal infections. Acute rheumatic fever can lead to long term heart damage
62 known as rheumatic heart disease in children 5-14, resulting in 282,000 new cases each year.¹

63

64 GAS pharyngitis is typically diagnosed by rapid antigen detection test (RADT) which requires a posterior
65 pharyngeal swab sample and provides a positive or negative result usually within 10 minutes. If the
66 RADT is negative, a throat culture is commonly performed requiring laboratory analysis, taking
67 additional time.² Wide-spread usage of RADT has been a valuable tool in detecting strep throat, and has
68 simultaneously reduced the overprescription of antibiotics.³ Most importantly, RADTs are inexpensive,
69 offer reasonable sensitivity and specificity, and have short turnaround times.^{4,5} Molecular testing, such as
70 the cobas® liat system (polymerase chain reaction, PCR), is also available requiring a posterior
71 pharyngeal swab and instrumentation.⁶ PCR technology is valuable due to its increased sensitivity at
72 detecting GAS.⁷ Pharyngeal swabs are uncomfortable, sometimes acting as a deterrent for children and
73 adults but it is important to confidently diagnose bacterial pharyngitis not only for the long-term health of
74 the patient but also to avoid over-prescription of antibiotics.¹

75

76 Saliva sampling holds significant promise; saliva is an accessible diagnostic biospecimen for point-of-
77 care devices as it is easy to collect, handle, and test.^{8,9} Here, we present an alternative sample collection
78 device called CandyCollect developed in our lab,^{10,11,12} and we show for the first time that the
79 CandyCollect device can be used in conjunction with an ‘on the market’ GAS RADT. Inspired by a
80 lollipop, the CandyCollect device is a polystyrene sampling tool that has open fluidic channels on one
81 side and a strawberry-flavored isomalt candy coating on the back and sides. While the user enjoys the
82 candy, pathogens in saliva are collected in the open fluidic channels.^{10,11,12} There are multiple sampling
83 devices currently available that resemble a lollipop but lack some of the built-in features that make the
84 CandyCollect device unique. For instance, Self-LolliSponge™, V-check COVID-19, and Whistling
85 COVID-19 are saliva collection devices that allow the user to self-collect saliva with a minimally
86 invasive protocol, but while these devices resemble a lollipop form they do not contain candy and do not
87 look like a lollipop.^{13,14}

88

89 Our prior research determined that the open fluidic channel in the CandyCollect device prevents the
90 tongue from removing bacteria, effectively collecting and accumulating the sample for future analysis.¹⁰
91 We have previously demonstrated the functionality of the CandyCollect device with an at-home human
92 subjects study that focused on the collection of commensal bacteria for the detection of *Staphylococcus*
93 *aureus* and *Streptococcus mutans* using qPCR.¹¹ We found that the CandyCollect device can successfully
94 capture commensal bacteria in an at-home setting, is stable through standard shipping without
95 refrigeration or other cooling mechanisms, and bacteria can be eluted and quantified using qPCR.¹¹ The
96 study also asked users to compare the CandyCollect device to two other commercial methods of
97 collection—a spit tube and ESwab™; users ranked the CandyCollect device as their preferred method of
98 oral sampling. Lastly, it was determined that the CandyCollect device is functional after storage for up to
99 one year.¹¹ Subsequently, we tested the CandyCollect device in a clinical setting, enrolling 30 pediatric
100 patients, aged 5-14 years who had positive results from pharyngeal swabs processed with RADT as part
101 of their clinical care.¹² Results from the CandyCollect device (qPCR analysis) had 100% concordance
102 with the positive results from their clinical care. Further, most children preferred the CandyCollect device
103 over pharyngeal swabs and mouth swabs.¹²

104

105 Our prior work used qPCR to detect bacteria (*S. pyogenes*, *S. mutans*, *S. aureus*) collected on the
106 CandyCollect devices, which is more sensitive than RADTs but requires specific equipment and is not
107 accessible to a home setting or some clinics. Here, we demonstrate that the CandyCollect device can be
108 integrated with a commercially available RADT as an alternative sample collection tool to the posterior
109 pharyngeal swab commonly packaged with RADT kits. To the best of our knowledge, our work presents
110 the first example of integrating a saliva collection method (the CandyCollect device) with a GAS RADT
111 . In addition, we demonstrate that our integrated protocol can achieve a positive signal on previously
112 frozen clinically sampled CandyCollect devices collected from pediatric patients.¹²

113

114 **Material & Methods**

115

116 **Fabrication of CandyCollect devices**

117

118 Device fabrication was described in our prior work.^{10,11,12} See SI for full description.

119

120 **Capture, elution, and detection of *S. Pyogenes***

121

122 *Capture of S. pyogenes on the CandyCollect device*

123 CandyCollect devices were incubated with 50 µL of *S. pyogenes* suspended in saliva for 10 min with the
124 following concentrations: 1.0×10^9 , 1.0×10^7 , 1.0×10^6 , 5.0×10^5 , 1.5×10^5 CFU/mL.¹ Additionally, we
125 incorporated, *S. pyogenes* at 1×10^9 CFU/mL suspended in THY liquid media as a positive control and
126 filtered pooled saliva as a negative control.

127

128 *Elution of S. pyogenes from the CandyCollect device*

129 Upon completion of the 10 min incubation time, the CandyCollect devices were placed in 14 mL round-
130 bottom polypropylene test tubes (Falcon CAT# 352059) that contained elution reagents, shaken for 15 s,
131 and eluted for another 45 s.

132

133 For the majority of experiments, the primary elution reagents used were 2.0 M Sodium Nitrite (Reagent
134 A) and 0.4 M Acetic Acid (Reagent B), obtained from the Areta Strep A Swab Test Kit™ (Easy@Home,
135 CAT# ARST-100S). Elution solutions of 100 µL of Reagents A and B were prepared for each rapid test,
136 resulting in 200 µL total volume. This volume was increased to 200 µL of each reagent for a total of 400
137 µL of elution solution for our experiment that directly compared our integrated workflow with the kit's
138 established workflow (per manufacturer's instructions). The solution was then aliquoted into 14 mL tubes
139 for the CandyCollect device or the kit-provided tubes for the swabs.

140
141 Other reagents tested as elution solutions included (1) ESwab™ buffer (Becton, Dickinson and Company,
142 Cat # R723482) with 1% Mineral Oil (Thermo Scientific™, CAT#AC415080010), (2) ESwab™ buffer
143 with 5% ethanol (3) ESwab™ buffer with 2% SDS, and (4) phosphate-buffered saline (PBS) (Fisher
144 Scientific, Cat# BP2944100) with 1% Proteinase K (Thermo Scientific™, Cat# EO0491).^{10,11}

145
146 *Clinical sample integration*
147 One of the CandyCollect devices from each replicate set was eluted and analyzed via qPCR following the
148 protocol established in our prior work.^{11,12} The second device was used to test the integrated
149 CandyCollect-Areta™ protocol. Six CandyCollect devices were chosen to test with a requirement that
150 both the replicate CandyCollect and the ESwab™ have low Ct values scores (a CandyCollect was not
151 chosen if the replicate had a low Ct but the ESwab™ did not). It should be noted that we tested the
152 replicate CandyCollect device, not the device that was eluted for qPCR. To prevent inconsistencies with
153 the test strips, all test strips used during a given experiment came from the same box and lot number. For
154 quality assurance, the box was validated per Areta™ new package protocol using the provided negative
155 and positive controls before any tests were started. They were also secondarily checked by the researchers
156 using pooled saliva as a negative control before testing the clinical samples. Clinical sample
157 CandyCollect devices were removed from a -80 °C freezer and thawed on ice for 10 min before testing.
158 Independent observers, away from the testing area, were given verbal instructions to not discuss results
159 and were given an insert from the Areta™ box that instructs what is considered a negative or positive test
160 result (Figure S1). Negative control devices were inoculated using pooled saliva and were included
161 arbitrarily among the clinical devices. Two strips were tested for each device. At the 18 min mark, the
162 strips were placed inside a sterile OmniTray™ (ThermoScientific™ Nunc™, CAT# 140156) with a clear
163 lid. With the strips inside the tray, independent observers were asked to record whether they thought the
164 test to be negative or positive.

165 166 **Analysis of lateral flow immunoassay strips**

167
168 *Interpretation of lateral flow immunoassay strip readout by eye*
169 Once the CandyCollect devices were eluted for 1 min, a lateral flow immunoassay strip was immersed
170 into the eluted solution. The immunoassay strip was held in the solution until the solution wicked up the
171 testing area on the immunoassay strip. Upon wicking, a timer was set for 18 min at which point the
172 immunoassay strip was viewed by two researchers and scanned (Hewlett-Packard, HP OfficeJet Pro6978,
173 SN# TH0AK4N0YT). All readouts conducted in the lab were determined by eye from each of the two
174 researchers after 18 min per the manufacturer's instructions which indicate that results are valid from 10
175 to 20 min after the test strip is removed from the elution solution. As noted in the Results section, for

176 clinical samples, test strips were viewed by two researchers and three independent observers who are not
177 authors of this publication.

178

179 *Quantification of signal on Areta lateral flow immunoassay strip via optical analysis*

180 The scanned LFA strips were analyzed using a custom image analysis Python script, drawing on
181 algorithms similar to previously published work.¹⁵ Images of each strip were digitally cropped from an
182 original full-color image obtained by the HP scanner, yielding multiple 25 x 100 pixel images. These
183 cropped images were then converted to monochrome and subsequently inverted. Profiles of digital
184 numbers against pixel location were obtained by averaging the rows for each strip. The script pinpoints
185 the test line peak signal values and locations from the profiles. For each profile, two regions of interest
186 (ROIs) spanning between 5 to 10 pixels were manually selected, approximately 30 pixels from both sides
187 of the peak. These two ROIs, selected from the non-reactive part of the membrane, establish the baseline.
188 The baseline is computed as the average digital number from these two ROIs. The signal-to-baseline
189 ratio (SBR) is calculated as the ratio of the peak signal of the test line from the profile divided by the
190 baseline.

191 The positivity threshold is a predetermined value of the SBR above which the test results are deemed
192 positive. It is derived from image analysis of the three negative controls collected for each experiment and
193 is calculated from the following equation:

194

$$\text{Positivity Threshold} = \mu\text{SBR} + 3\sigma\text{SBR}$$


195 where μSBR and σSBR are the average signal-to-baseline and the standard deviation signal-to-baseline of
196 the three negative controls, respectively. The python script determines the negative signal by analyzing a
197 segment of the profile located at a specific distance from the negative control line peak, a distance that is
198 informed by the test line peak locations in positive test strips. This approach ensures that the segment
199 location accurately reflects the expected position of a negative control test line.

200 **Results and Discussion**

201 *Integration of the CandyCollect device with a commercially available lateral flow immunoassay for GAS* 202 *detection*

203 The CandyCollect device (Figure 1a.) is a lollipop-inspired oral sampling device that uses plasma-treated
204 open fluidic channels to capture pathogens in saliva as the user consumes the strawberry-flavored isomalt
205 candy.^{10,11,12} We integrated the CandyCollect device into the Areta Strep A Swab Test™ protocol by
206 substituting the kit-provided swab with our novel oral sampling device in order to provide a more
207 comfortable testing experience. There are several commercially available LFA for GAS detection. We
208 explored three commercially available tests, Areta Strep A Swab Test™, Abbot BinaxNow Strep A Card
209™, and Quidel QuickVue Dipstick Strep A Test™, and compared them based on limit of detection and
210 overall user workflow. The Areta Strep A Swab Test™ kit was selected as the rapid strep throat test to
211 integrate with the CandyCollect device as it had the lowest limit of detection (1.5×10^5 CFU/mL *S.*
212 *pyogenes*) and the workflow of the test allowed for the most direct substitution of the throat swab
213 sampling method.

214




215
216 **Figure 1.** (a) Schematic of the CandyCollect Device. The open fluidic channels milled into the head of the plasma-treated
217 polystyrene stick allow pathogens to adhere over sampling time as the user consumes the isomalt candy. (b) Workflow to
218 incorporate sampling with the CandyCollect device with the Areta Strep A Swab Test™ protocol. (i) Elution solution is prepared
219 before sampling in the kit-provided tube by combining 100 µL (2 drops) of Reagent A (2.0 M sodium nitrite) and 100 µL (2
220 drops) of Reagent B (0.4 M acetic acid) for a total elution solution volume of 200 µL. (ii) To sample, the participant places the
221 CandyCollect device in their mouth and consumes the isomalt candy on the CandyCollect device until the candy is completely
222 dissolved. *S. pyogenes* collects on the plasma-treated open-fluidic channels within the CandyCollect device over time. (iii) After
223 sampling, the CandyCollect device is added to the tube of elution solution, and the tube is capped and shaken for 15 s to ensure
224 that the elution solution reaches the channels. (iv) The tube is then set aside for 1 minute. (v) The tube is then uncapped, and the
225 kit-provided test strip is dipped into the elution solution for 10 s or until the fluid visibly starts to wick on the testing section of
226 the lateral flow strip. Test results are valid for 10 to 20 min after complete wicking. (vi) The presence of a test and control line
227 indicates a positive result; a control line only indicates a negative result.

228
229 Our optimized integrated workflow is outlined in Figure 1b. Rather than taking a sample directly from the
230 throat with the kit-provided swab, the user's saliva sample is gathered using the channels of the
231 CandyCollect device. From there, the device is added to a reduced volume of 200 µL of the kit-provided
232 elution reagents [Reagent A (2.0 M sodium nitrite) and Reagent B (0.4 M acetic acid)]. The CandyCollect
233 device is larger than the kit-provided swab, so our protocol includes a larger round-bottom tube to
234 accommodate the device and ensure effective coverage of the CandyCollect channels when immersed in
235 elution solution. The user directly tests the elution solution by dipping the LFA strip following the
236 manufacturer's instructions. As is common with LFAs, there is a control line and a test line, the presence
237 of both lines indicates a positive result, while the presence of only the control line indicates a negative
238 result. It is important to note that the sample tested in this workflow is saliva rather than a direct
239 collection of bacteria from the user's throat, like in a throat swab.

240 241 *Optimization of sample preparation and lateral flow assay workflow*

242 We first evaluated the optimal reagents to elute *S. pyogenes* or *S. pyogenes* antigens from the
243 CandyCollect device. We compared the strength of the test line signal when using the kit-provided
244 reagents [Reagent A (2.0 M sodium nitrite) and Reagent B (0.4 M acetic acid)] to the signal strength
245 when using other methods our lab previously developed for eluting *S. pyogenes* prior to qPCR detection
246 (Figure 2).¹⁰ The elution methods used in the evaluation were ESwab™ buffer with 5% ethanol,
247 ESwab™ buffer with 2% sodium dodecyl sulfate, ESwab™ buffer with 1% mineral oil and PBS with 1%
248 Proteinase K.^{10,11} Test strips were imaged 18 minutes after elution. Quantification of the test line and
249 control line intensity are shown in Figure 2a. Further, results were determined by eye per the

250 manufacturer's instructions also at 18 minutes after elution and are reported below the corresponding
251 scanned test strip. The scanned images are for visual aid and may not align with the reported results by
252 eye due to quality of imaging.
253




254
255 **Figure 2.** Optimization of elution solution. (a) Image analysis of the LFA strips from the elution comparison test shows that the
256 Areta™ kit-provided reagents [Reagent A (2.0 M sodium nitrite) and Reagent B (0.4 M acetic acid)] result in the strongest signal
257 intensity when compared with previous successful elution solutions developed for the CandyCollect device with qPCR
258 analysis.^{10,11} (b) Representative images of LFA strips quantified in A (Figure S2 shows images from three independent
259 experiments). *S. pyogenes* at 1.0x10⁶ CFU/mL suspended in filtered pooled saliva was used for all samples. Reagents tested from
260 left to right are: the kit-provided Reagent A (2.0 M sodium nitrite) and Reagent B (0.4 M acetic acid), ESwab™ buffer with 5%
261 ethanol (EtOH), ESwab™ buffer with 2% sodium dodecyl sulfate (SDS), ESwab™ buffer with 1% mineral oil (M. Oil), and
262 phosphate buffered saline (PBS) with 1% Proteinase K (ProK).
263

264 The kit-provided reagents resulted in the strongest test line signal across all three experiments (Figure 2
265 and S2) and were selected as the optimal elution solution for the integrated workflow. ESwab™ buffer
266 with 5% ethanol and PBS with 1% Proteinase K resulted in negative or markedly fainter positive results
267 than the kit-provided reagents. ESwab™ buffer with 2% sodium dodecyl sulfate and ESwab™ buffer
268 with 1% mineral oil consistently resulted in a negative test line, making them unfit as an elution solution
269 for the rapid test kit.

270
271 Although the manufacturer's instructions specify that the strength of the test line signal is not indicative
272 of the concentration of *S. pyogenes*, to aid the user's ability to read test results easily and accurately, we
273 investigated possible alterations to the rapid test workflow to increase test line signal strength. To increase
274 the concentration of *S. pyogenes* antigens in solution for testing, we reduced the elution solution volume
275 from 400 μL to 200 μL. We investigated the effects of the alteration by directly comparing the rapid test
276 results across a range of *S. pyogenes* concentration samples 1.5x10⁵ to 1.0x10⁷ CFU/mL, with 1.5x10⁵
277 CFU/mL advertised as the kit's limit of detection (Figure 3). In order to achieve a non-biased readout, an
278 algorithm was written in Python to evaluate the intensities of the lines, relative to the positivity threshold
279 (Figure S3, S4, S5, & S6). Our intention was to eliminate user discrepancies when interpreting the strips

280 results by eye. The quantified results from three independent experiments are plotted in Figure 3a. Results
281 were also determined by eye per the manufacturer's instructions 18 minutes after testing the elution
282 solution and are reported below the corresponding scanned test strip (Figure 3b). The scanned images are
283 for visual aid and may not align with the reported results due to quality of imaging.
284



285 **Figure 3.** Reduction of elution volume results in a stronger test line signal. Areta Strep A Swab Test™ results using different
286 elution reagent volumes, 200 μL (our optimized reduced volume) and the 400 μL (the volume specified in the Areta test kit
287 instructions). (a) Quantification of three independent experiments with the mean and standard error of the mean (SEM). The
288 positivity threshold (green dashed line) is calculated as the mean + three standard deviations of the signal-to-baseline ratio (SBR)
289 taken from the negative controls (Figure S5 & S6). (b) Representative images of LFA strips quantified in A (Figure S3 shows
290 images from three independent experiments). Elution reagents used were Reagent A (2.0 M sodium nitrite) and Reagent B (0.4 M
291 acetic acid) provided in the rapid test kit. The different elution volumes were tested using samples across a range of
292 concentrations from 1.5×10^5 to 1.0×10^7 *S. pyogenes* CFU/mL.
293
294

295 When testing samples at 1.5×10^5 CFU/mL, the 400 μL elution solution volume resulted in very faintly
296 positive to negative results by eye, however, the reduced 200 μL elution solution volume resulted in
297 positive results across three independent experiments (Figure 3b). Image quantification revealed that for
298 1.5×10^5 CFU/mL, the 200 μL elution solution volume resulted in a signal that was above or at the
299 positivity threshold, whereas using the 400 μL elution solution volume resulted in a signal that was below
300 the positivity threshold (Figure 3a). This trend was further confirmed with the 5.0×10^5 CFU/mL samples,
301 as the strength of the test line signal by eye from the samples using the 200 μL elution solution volume
302 was consistently greater than the test line signal of the samples using the 400 μL elution solution volume;
303 quantification of the test line signal intensity of the 5.0×10^5 CFU/mL samples showed that using the 200
304 μL elution solution volume resulted in a signal that was above the positivity threshold whereas using the

305 400 μL elution solution volume resulted in a signal that was below the positivity threshold (Figure 3a).
306 For 1.0×10^6 and 1.0×10^7 CFU/mL samples, both conditions resulted in strong positive results and the
307 difference in strength of signal was less prominent based on image quantification and by eye (Figure 3a
308 and b). Taken together, the results showed the benefit of reducing the elution solution volume to 200 μL ,
309 and this change was implemented into our integrated workflow (Figure 1b).


310

311 *CandyCollect sampling method gives comparable results to the kit-provided swab based on in vitro*
312 *experiments in spiked saliva*

313 To compare the efficacy of the CandyCollect device as an alternative sampling method to the kit-provided
314 swab, we evaluated the strength of the test lines across three different sampling methods and the two
315 different elution solution volumes (Figure 4). For our experiments, we used a 50 μL sample of *S.*
316 *pyogenes* in saliva to inoculate the channels of the CandyCollect device for 10 minutes as an *in vitro*
317 simulation of bacterial collection from saliva. To compare to the CandyCollect device, we deposited
318 samples onto the kit-provided swab in two ways: (i) 50 μL of the sample directly pipetted onto the swab
319 (to directly compare the same sample volume that was pipetted on the CandyCollect device) and (ii)
320 dipping the swab directly into the saliva sample. An important limitation of the comparisons between
321 swabs and the CandyCollect device is that the swab data from the manufacturer is completed at the back
322 of the throat whereas in this work we used bacteria suspended saliva; however, we decided to compare the
323 sampling methods this way due to practicality of the experimental setup.

324

325



326
 327 **Figure 4.** The CandyCollect device gives comparable results to kit-provided swabs. **(a)** Areta Strep A Swab Test™ results using
 328 three different sampling methods with the optimized (reduced elution solution volume) workflow (CandyCollect – 50 μ L
 329 pipetted; kit-provided swab – 50 μ L pipetted; and kit-provided swab – dipped into sample all eluted in 200 μ L) as well as the
 330 original Areta workflow (kit-provided swab – dipped into sample eluted in 400 μ L). All four methods were tested across a range
 331 of concentrations from 1.5×10^5 to 1.0×10^7 CFU/mL *S. pyogenes* in pooled human saliva. The images were taken at 18–20 min,
 332 and the result indicated (positive or negative) was determined by eye according to the test instructions at 18 min. Images shown
 333 are representative of three independent experiments. **(b)** Quantification of three independent experiments with the mean and
 334 standard error of the mean (SEM). The positivity threshold (green dashed line) is calculated as the mean + three standard
 335 deviations of the signal to baseline ratio (SBR) taken from the negative controls (see SI for further details).
 336

337 All four methods were tested across a range of concentrations from 1.5×10^5 to 1.0×10^7 CFU/mL *S.*
 338 *pyogenes* suspended in filtered pooled human saliva, as well as a negative control of only saliva. For this
 339 experiment, we followed our optimized integrated workflow with a 200 μ L elution volume for the three
 340 different methods. We also tested a condition using the kit directed workflow with a 400 μ L elution
 341 volume with the swab dipped into the saliva sample. Both the 50 μ L 1.5×10^5 CFU/mL sample on the
 342 CandyCollect device and the dipped samples on the swab gave positive results, however, the 50 μ L
 343 sample pipetted on the swab produced a negative result by eye (Figure 4a). Image quantification revealed
 344 that pipetting 50 μ L of 1.5×10^5 CFU/mL *S. pyogenes* and following up with 200 μ L of elution solution
 345 onto the CandyCollect device, resulted in a signal below that positivity threshold. Image quantification
 346 for the Areta kit swab, using the same conditions, demonstrated a similar result, being at or just below the
 347 positivity threshold (Figure 4b). At 5×10^5 CFU/mL *S. pyogenes* all four methods resulted in positive tests


348 that were visible by eye (Figure 4a). As the image quantification shows, two out of the three methods in
 349 this experiment, which used a 200 μL elution volume, resulted in a signal above the positivity threshold
 350 line. In contrast, the Areta kit swab, following Areta's recommended elution volume (400 μL), resulted in
 351 a signal at the positivity threshold line (Figure 4b). At 1.0×10^6 and 1.0×10^7 CFU/mL *S. pyogenes* all four
 352 conditions resulted in positive tests. The results were consistent across all three experiments, specifically
 353 that the CandyCollect device sample at 1.5×10^5 CFU/mL *S. pyogenes* was read as positive by eye, further
 354 supporting it as a possible alternative sampling method (Figure 4a). Lastly, at 1.0×10^6 and 1.0×10^7 mean
 355 values for all conditions were above or at the positivity threshold (Figure 4b).

356

357 Of note, there were minor differences between the results in Figures 3a (left plot) and 4b (top left plot)
 358 using the same experimental conditions (50 μL of *S. pyogenes* in saliva pipetted onto the CandyCollect
 359 device and eluted in 200 μL). The difference across these two sets of experiments is likely due to
 360 manufacturing inconsistencies across LFA strips and varying amounts of leaching dye that results in a
 361 higher background and therefore higher positivity threshold in Figure 4b than in Figure 3a.

362

363 **Clinical sample results**



364

365 **Figure 5.** Rapid test results from the CandyCollect device samples obtained from children with GAS pharyngitis. Testing was
 366 completed over the course of three days. Participants 1-3 had positive test results on two replicate LFA strips eluted from the
 367 sample CandyCollect device. For Participant 6, one LFA strip was positive and the duplicate LFA strip was negative. The LFA
 368 strips for participant 5 did not have universal agreement among independent observers and researchers. Independent observers
 369 were shown LFA strips in an arbitrary order. The scanned images are for visual aid and may not align with the reported results
 370 due to quality of imaging.

371

372 Subsequently, we tested the CandyCollect device in a clinical setting, enrolling 30 pediatric patients, aged
 373 5-14 years who had positive results from pharyngeal swabs processed with RADT as part of their clinical
 374 care.¹² We performed the optimized protocol (shown in Figure 1) on six CandyCollect devices from six
 375 participants. We performed the LFA in duplicate for each of the CandyCollect device (the 200 μL elution
 376 volume allowed for two LFA strips). We asked three independent observers who are not co-authors on
 377 this manuscript to evaluate LFA strips from negative controls and human subject samples shown to them
 378 in an arbitrary order. Two researchers, who are co-authors on this manuscript, also viewed the test strips,
 379 and all results are reported in Figure 5. The human subject samples were tested over the course of three
 380 days, with fresh negative controls interspersed each day. Independent observers were shown the AretaTM
 381 protocol and were told that a line, even a faint line, is positive and no line is negative, as instructed by the

382 Areta™ protocol (see Figure S8). We requested that the independent observers not discuss or share their
383 answers with each other.

384
385 Additional red pigment due to leftover candy was common on the devices from the clinical samples,
386 resulting in background pinkish/red color along the length of the test strip, particularly in Participants 1,
387 2, 3, and 5. In the future we plan to test other candy colors, such as yellow, to avoid this background
388 signal. Further, due to the high background, we did not quantify these images as the human eye is able to
389 discern a positive signal despite the background and the Areta™ protocol instructions call for reading the
390 strips by eye. Twenty out of 22 test strips had unanimous agreement as being either positive or negative;
391 the two that did not have agreement among the independent observers came from the same CandyCollect
392 device (from Participant 5) on analysis day 3; this CandyCollect device, still had candy on the device
393 which caused the testing area to be pinkish/red. The combination of the added pigment and the possibility
394 of the concentration of *S. pyogenes* being near the minimal detection limit for this sample may have led to
395 the mixed observations. Participants 1-3 had positive test results on two replicate LFA strips eluted from
396 the sample CandyCollect device. For Participant 6, one LFA strip was positive and the duplicate LFA
397 strip was negative. Taken together, our results show that the CandyCollect devices from children with
398 GAS pharyngitis can be tested using LFA rapid tests. Further work is needed to reduce the red
399 background (by changing the candy color), to expand the sample size, and to improve detection in
400 samples with less abundant bacteria. We note that the Areta Strep A Swab Test™ was designed to be
401 integrated with a pharyngeal swab, which will likely have different levels of bacteria compared to a saliva
402 sample; further development of the CandyCollect device surface properties to be specific to capturing
403 GAS may improve the levels of bacteria collected and is a subject of future work.

404 405 **Conclusion**

406
407 In this work, we combined a previously reported novel saliva sampling device with an available GAS
408 RADT. This was achieved by altering the Areta™ kit protocol: (1) replacing the pharyngeal swab with
409 the CandyCollect device, (2) substituting the kit test tube for a larger round-bottom tube (to accommodate
410 the larger CandyCollect device), and (3) adjusting the elution volume. Other elution solutions were
411 considered but results showed that elution reagents provided by the manufacturer performed best. *In vitro*
412 experiments showed we can consistently achieve a positive test strip signal with the “minimal detection
413 limit” indicated by the manufacturer. Furthermore, previously frozen CandyCollect clinical samples from
414 pediatric patients diagnosed as positive for GAS via RADT performed on pharyngeal swabs as part of
415 their clinical care also yielded a positive signal while following our optimized protocol. Future research
416 will be conducted remotely with children and their parents to continue to test usability and practicality of
417 performing our CandyCollect-rapid test protocol in a home setting. Future studies will also be done to
418 examine other bacterial and viral pathogens found in saliva that can be captured by the CandyCollect
419 device and integrated with rapid tests, such as SARS-CoV-2. We will also continue our ongoing
420 collaborative studies in clinical settings to build our sample size with patients and to further integrate their
421 feedback.

422 423 **Conflict of Interest Disclosures**

424 Ashleigh B. Theberge, Xiaojing Su, Erwin Berthier, and Sanitta Thongpang filed patent 63/152,103
425 (International Publication Number: WO 2022/178291 A1) through the University of Washington on the

426 CandyCollect oral sampling device. J. Carlos Sanchez, Timothy R. Robinson, Ayokunle O. Olanrewaju,
427 Erwin Berthier, and Ashleigh B. Theberge filed patent 63/683,571 through the University of Washington
428 on a related platform. Ashleigh B. Theberge reports filing multiple patents through the University of
429 Washington and receiving a gift to support research outside the submitted work from Ionis
430 Pharmaceuticals. Erwin Berthier is an inventor on multiple patents filed by Tasso, Inc., the University of
431 Washington, and the University of Wisconsin. Sanitta Thongpang has ownership in Salus Discovery,
432 LLC, and Tasso, Inc. Erwin Berthier has ownership in Salus Discovery, LLC, and Tasso, Inc. and is
433 employed by Tasso, Inc. However, this research is not related to these companies. Sanitta Thongpang,
434 Erwin Berthier, and Ashleigh B. Theberge have ownership in Seabright, LLC, which will advance new
435 tools for diagnostics and clinical research, potentially including the CandyCollect device. The terms of
436 this arrangement have been reviewed and approved by the University of Washington in accordance with
437 its policies governing outside work and financial conflicts of interest in research. The other authors have
438 no conflicts of interest to disclose.

439

440 **Author Contributions**

441 J.C.S., I.R., and V.A.M.S., contributed equally to this work. J.C.S., I.R., V.A.M.S., X.S., E.B., S.T., and
442 A.B.T conceptualized the research integrating the CandyCollect with RADTs. A.B. E.A., E.R.W., G.P.D.,
443 E.B., S.T., and A.B.T. conceptualized the pediatric clinical study, and E.R.W. and G.P.D. oversaw study
444 execution. J.C.S. and I.R. milled the CandyCollect devices. J.C.S., I.R., V.A.M.S., and D.B.H fabricated
445 candy devices and prepared devices for the human subjects research, including designing experimental
446 protocols/engineering designs. J.C.S., I.R., and V.A.M.S. X.S., W.-C.T., reviewed the literature that
447 informed the study, designed the biological experiments, conducted biological experiments and data
448 collection. A.B. advised on study design and execution, enrolled and interacted with the participants,
449 collected the samples and user surveys, and accessioned and shipped the samples. E.A. advised on study
450 design and execution, advised on all regulatory aspects, drafted the study protocol and survey
451 instruments, and obtained Institutional Review Board (IRB) approval. J.C.S., T.R.R., M.M.C., A.O.O.,
452 E.B., and A.B.T. developed and refined data analysis methods for quantifying RADT results. All authors
453 analyzed and interpreted the data. J.C.S., I.R., V.A.M.S., X.S., T.R.R., M.M.C., S.T., and A.B.T., wrote
454 sections of the manuscript. All authors revised and approved the manuscript.

455

456 **Acknowledgement**

457 All phases of this study were supported by National Institutes of Health grants (R21AI166120,
458 R35GM128648 (the latter specifically supported some of the in-lab developments and procedure
459 developments)), the Washington Research Foundation, a STEP grant from UW CoMotion, the Camille
460 and Henry Dreyfus Foundation, and an Alfred P. Sloan Research Fellowship. The content is solely the
461 responsibility of the authors and does not necessarily represent the official views of the National Institutes
462 of Health or other funding sources. We would like to thank the participants in the clinical study and the
463 independent observers.

464


465 **References**

- 466 1. Walker, M. J.; Barnett, T. C.; McArthur, J. D.; Cole, J. N.; Gillen, C. M.; Henningham, A.;
467 Sriprakash, K. S.; Sanderson-Smith, M. L.; Nizet, V. Disease Manifestations and Pathogenic
468 Mechanisms of Group A Streptococcus. *Clin Microbiol Rev* **2014**, *27* (2), 264–301.
469 <https://doi.org/10.1128/CMR.00101-13>.

- 470 2. Shulman, S. T.; Bisno, A. L.; Clegg, H. W.; Gerber, M. A.; Kaplan, E. L.; Lee, G.; Martin, J. M.;
471 Van Beneden, C.; Infectious Diseases Society of America. Clinical Practice Guideline for the
472 Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious
473 Diseases Society of America. *Clin Infect Dis* **2012**, *55* (10), e86-102.
474 <https://doi.org/10.1093/cid/cis629>.
- 475 3. Worrall, G.; Hutchinson, J.; Sherman, G.; Griffiths, J. Diagnosing Streptococcal Sore Throat in
476 Adults. *Can Fam Physician* **2007**, *53* (4), 666–671.
- 477 4. De Schuyter, K.; Boelens, J.; Messiaen, A.-S.; Schelstraete, P.; Verhasselt, B.; Huis In't Veld, D.;
478 Callens, S.; Sermijn, E.; Vande Weygaerde, Y.; Vandendriesche, S. Rapid Detection of *S.*
479 *Pyogenes* and *S. Pneumoniae* in Pleural Fluid for Diagnosis of Parapneumonic Empyema. *Eur J*
480 *Clin Microbiol Infect Dis* **2024**, *43* (1), 195–201. <https://doi.org/10.1007/s10096-023-04710-w>.
- 481 5. Korenkov, M.; Poopalasingam, N.; Madler, M.; Vanshylla, K.; Eggeling, R.; Wirtz, M.; Fish, I.;
482 Dewald, F.; Gieselmann, L.; Lehmann, C.; Fätkenheuer, G.; Gruell, H.; Pfeifer, N.; Heger, E.;
483 Klein, F. Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify
484 Potentially Infectious Individuals. *Journal of Clinical Microbiology* **2021**, *59* (9),
485 10.1128/jcm.00896-21. <https://doi.org/10.1128/jcm.00896-21>.
- 486 6. Jaggi, P.; Leber, A. Molecular Testing for Group A Streptococcal Pharyngitis: To Test or Not To
487 Test, That Is the Question. *Journal of the Pediatric Infectious Diseases Society* **2021**, *10* (2), 65–
488 67. <https://doi.org/10.1093/jpids/pix106>.
- 489 7. Banerjee, D.; Crawford, J.; Harrison, C. J.; Rha, B.; Lively, J. Y.; Selvarangan, R. 2185. Group A
490 Streptococcus (GAS) Detection by PCR in Children with Viral Acute Respiratory Illness and
491 Healthy Children. *Open Forum Infectious Diseases* **2019**, *6* (Supplement_2), S742–S743.
492 <https://doi.org/10.1093/ofid/ofz360.1865>.
- 493 8. Henson, B. S.; Wong, D. T. Collection, Storage, and Processing of Saliva Samples for
494 Downstream Molecular Applications. *Oral Biology: Molecular Techniques and Applications*
495 **2010**, 21–30. https://doi.org/10.1007/978-1-60761-820-1_2.
- 496 9. Nonaka, T.; Wong, D. T. W. Saliva Diagnostics. *Annu Rev Anal Chem (Palo Alto Calif)* **2022**, *15*
497 (1), 107–121. <https://doi.org/10.1146/annurev-anchem-061020-123959>.
- 498 10. Lee, U. N.; Su, X.; Hieber, D. L.; Tu, W.; McManamen, A. M.; Takezawa, M. G.; Hassan, G. W.;
499 Chan, T. C.; Adams, K. N.; Wald, E. R.; DeMuri, G. P.; Berthier, E.; Theberge, A. B.; Thongpang,
500 S. CandyCollect: At-Home Saliva Sampling for Capture of Respiratory Pathogens. *Lab Chip*
501 **2022**, *22* (18), 3555–3564. <https://doi.org/10.1039/D1LC01132D>.
- 502 11. Tu, W.-C.; McManamen, A. M.; Su, X.; Jeacopello, I.; Takezawa, M. G.; Hieber, D. L.; Hassan,
503 G. W.; Lee, U. N.; Anana, E. V.; Locknane, M. P.; Stephenson, M. W.; Shinkawa, V. A. M.; Wald,
504 E. R.; DeMuri, G. P.; Adams, K.; Berthier, E.; Thongpang, S.; Theberge, A. B. At-Home Saliva
505 Sampling in Healthy Adults Using CandyCollect, a Lollipop-Inspired Device. *bioRxiv* **2023**,
506 2023.01.14.524039. <https://doi.org/10.1101/2023.01.14.524039>.
- 507 12. Tu, W.-C.; Robertson, I. H.; Blom, A.; Alfaro, E.; Shinkawa, V. A. M.; Hatchett, D. B.; Sanchez,
508 J. C.; McManamen, A. M.; Su, X.; Berthier, E.; Thongpang, S.; Wald, E. R.; DeMuri, G. P.;
509 Theberge, A. B. Capture of Group A Streptococcus by Open-Microfluidic CandyCollect Device
510 in Pediatric Patients. *medRxiv* **2024**, 2023.12.14.23299923.
511 <https://doi.org/10.1101/2023.12.14.23299923>.
- 512 13. Ottaviano, E.; Parodi, C.; Borghi, E.; Massa, V.; Gervasini, C.; Centanni, S.; Zuccotti, G.;
513 LollipopStudy Group; Bianchi, S. Saliva Detection of SARS-CoV-2 for Mitigating Company
514 Outbreaks: A Surveillance Experience, Milan, Italy, March 2021. *Epidemiol Infect* **2021**, *149*,
515 e171. <https://doi.org/10.1017/S0950268821001473>.
- 516 14. De Meyer, J.; Goris, H.; Mortelé, O.; Spiessens, A.; Hans, G.; Jansens, H.; Goossens, H.;
517 Matheeußen, V.; Vandamme, S. Evaluation of Saliva as a Matrix for RT-PCR Analysis and Two
518 Rapid Antigen Tests for the Detection of SARS-CoV-2. *Viruses* **2022**, *14* (9), 1931.
519 <https://doi.org/10.3390/v14091931>.

520 15. Smith, C. A.; Chang, M. M.; Kundrod, K. A.; Novak, E. N.; Parra, S. G.; López, L.; Mavume, C.;
521 Lorenzoni, C.; Maza, M.; Salcedo, M. P.; Carns, J. L.; Baker, E.; Montealegre, J.; Scheurer, M.;
522 Castle, P. E.; Schmeler, K. M.; Richards-Kortum, R. R. A Low-Cost, Paper-Based Hybrid Capture
523 Assay to Detect High-Risk HPV DNA for Cervical Cancer Screening in Low-Resource Settings.
524 *Lab Chip* 2023, 23 (3), 451–465. <https://doi.org/10.1039/D2LC00885H>.
525
526

Table of Contents/Abstract Figure



527
528